Skip to main content

Advertisement

Log in

The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors

Current Gastroenterology Reports Aims and scope Submit manuscript

Abstract

Purpose of review

The discovery of Helicobacter pylori and other organisms colonizing the stomach and the intestines has shed some light on the importance of microbiome in maintaining overall health and developing pathological conditions when alterations in biodiversity are present. The gastric acidity plays a crucial role in filtering out bacteria and preventing development of enteric infections. In this article, we discuss the physiology of gastric acid secretion and bacterial contribution to the composition of gastric and intestinal barriers and review the current literature on the role of proton pump inhibitors (PPIs) in the microbial biodiversity of the gastrointestinal tract.

Recent findings

Culture-independent techniques, such as 16S rRNA sequencing, have revolutionized our understanding of the microbial biodiversity in the gastrointestinal tract. Luminal and mucosa-associated microbial populations are not identical. Streptococcus is overrepresented in the biopsies of patients with antral gastritis and may also be responsible for the development of peptic ulcer disease. The use of PPIs favors relative streptococcal abundance irrespective of H. pylori status and may explain the persistence of dyspeptic symptoms in patients on PPI therapy. Increased risk of enteric infections has also been seen in patients taking PPIs. The overuse of PPIs leads to significant shift of the gastrointestinal microbiome towards a less healthy state.

Summary

With the advent of PPIs, many studies have demonstrated the significant changes in the microbial composition of both gastric and intestinal microbiota. Although they are considered relatively safe over-the-counter medications, PPIs in many cases are over- and even inappropriately used. Future studies assessing the safety of PPIs and their role in the development of microbiome changes should be encouraged.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ramsay PT, Carr A. Gastric acid and digestive physiology. Surg Clin North Am. 2011;91(5):977–82.

    Article  PubMed  Google Scholar 

  2. Zeng N, Athmann C, Kang T, et al. PACAP type I receptor activation regulates ECL cells and gastric acid secretion. J Clin Invest. 1999;104(10):1383–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yamaji N, Yokoo Y, Iwashita T, et al. Structural determination of two active compounds that bind to the muscarinic M3 receptor in beer. Alcohol Clin Exp Res. 2007;31:S9–S14.

    Article  PubMed  Google Scholar 

  4. Schubert ML, Makhlouf GM. Gastrin secretion induced by distention is mediated by gastric cholinergic and vasoactive intestinal peptide neurons in rats. Gastroenterology. 1993;104(3):834–9.

    Article  CAS  PubMed  Google Scholar 

  5. Orloff SL, Bunnett NW, Wong H, Walsh JH, Debas HT. Neural and hormonal mechanisms mediate the enterogastric reflex: a study in intestinal transplants in rats. Gastroenterology. 1991;101(3):734–42.

    Article  CAS  PubMed  Google Scholar 

  6. Phan J, Benhammou JN, Pisegna JR. Gastric hypersecretory states: investigation and management. Curr Treat Options Gastroenterol. 2015;13(4):386–97.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Schubert ML. Gastric acid secretion. Curr Opin Gastroenterol. 2016;32(6):452–60.

    Article  PubMed  Google Scholar 

  8. Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134(7):1842–60.

    Article  CAS  PubMed  Google Scholar 

  9. Takeuchi K, Endoh T, Hayashi S, Aihara T. Activation of muscarinic acetylcholine receptor subtype 4 is essential for cholinergic stimulation of gastric acid secretion: relation to D cell/somatostatin. Front Pharmacol. 2016;7:278.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Frick C, Rettenberger AT, Lunz ML, Breer H. Complex morphology of gastrin-releasing G-cells in the antral region of the mouse stomach. Cell Tissue Res. 2016;366(2):301–10.

    Article  CAS  PubMed  Google Scholar 

  11. Bitziou E, Patel BA. Simultaneous detection of gastric acid and histamine release to unravel the regulation of acid secretion from the guinea pig stomach. Am J Physiol Gastrointest Liver Physiol. 2012;303(3):G396–403.

    Article  CAS  PubMed  Google Scholar 

  12. Vuyyuru L, Schubert ML. Histamine, acting via H3 receptors, inhibits somatostatin and stimulates acid secretion in isolated mouse stomach. Gastroenterology. 1997;113(5):1545–52.

    Article  CAS  PubMed  Google Scholar 

  13. Schubert ML, Hightower J, Makhlouf GM. Linkage between somatostatin and acid secretion: evidence from use of pertussis toxin. Am J Phys. 1989;256(2 Pt 1):G418–22.

    CAS  Google Scholar 

  14. Beales ILP. Regulation of gastric function by gastrin releasing peptide. Gut. 2002;50(6):897–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yakabi K, Kawashima J, Kato S. Ghrelin and gastric acid secretion. World J Gastroenterol. 2008;14(41):6334–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Shimizu K, Li P, Lee KY, Chang TM, Chey WY. The mechanism of inhibitory action of secretin on gastric acid secretion in conscious rats. J Physiol. 1995;488(Pt 2):501–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Schmidt WE, Schenk S, Nustede R, Holst JJ, Folsch UR, Creutzfeldt W. Cholecystokinin is a negative regulator of gastric acid secretion and postprandial release of gastrin in humans. Gastroenterology. 1994;107(6):1610–20.

    Article  CAS  PubMed  Google Scholar 

  18. Konturek JW, Konturek SJ, Kwiecien N, et al. Leptin in the control of gastric secretion and gut hormones in humans infected with Helicobacter pylori. Scand J Gastroenterol. 2001;36(11):1148–54.

    Article  CAS  PubMed  Google Scholar 

  19. Shin JM, Munson K, Vagin O, Sachs G. The gastric HK-ATPase: structure, function, and inhibition. Pflugers Archiv. 2009;457(3):609–22.

    Article  CAS  PubMed  Google Scholar 

  20. Caplan MJ. The future of the pump. J Clin Gastroenterol. 2007;41(Suppl 2):S217–22.

    Article  CAS  PubMed  Google Scholar 

  21. Hersey SJ, Sachs G. Gastric acid secretion. Physiol Rev. 1995;75(1):155–89.

    CAS  PubMed  Google Scholar 

  22. Fujii T, Fujita K, Takeguchi N, Sakai H. Function of K(+)-Cl(−) cotransporters in the acid secretory mechanism of gastric parietal cells. Biol Pharm Bull. 2011;34(6):810–2.

    Article  CAS  PubMed  Google Scholar 

  23. Fellenius E, Berglindh T, Sachs G, et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase. Nature. 1981;290(5802):159–61.

    Article  CAS  PubMed  Google Scholar 

  24. Li H, Meng L, Liu F, Wei JF, Wang YQ. H+/K+-ATPase inhibitors: a patent review. Expert Opin Ther Pat. 2013;23(1):99–111.

    Article  CAS  PubMed  Google Scholar 

  25. Galmiche JP, Bruley Des Varannes S, Ducrotte P, et al. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers. Aliment Pharmacol Ther. 2004;19(6):655–62.

    Article  CAS  PubMed  Google Scholar 

  26. Shin JM, Kim N. Pharmacokinetics and pharmacodynamics of the proton pump inhibitors. J Neurogastroenterol Motil. 2013;19(1):25–35.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Sachs G, Shin JM. The basis of differentiation of PPIs. Drugs Today (Barc). 2004;40(Suppl A):9–14.

    CAS  Google Scholar 

  28. Shin JM, Sachs G. Restoration of acid secretion following treatment with proton pump inhibitors. Gastroenterology. 2002;123(5):1588–97.

    Article  CAS  PubMed  Google Scholar 

  29. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther. 2000;14(8):963–78.

    Article  CAS  PubMed  Google Scholar 

  30. Hatlebakk JG, Katz PO, Camacho-Lobato L, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14(10):1267–72.

    Article  CAS  PubMed  Google Scholar 

  31. Katsube T, Adachi K, Kawamura A, et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther. 2000;14(8):1049–56.

    Article  CAS  PubMed  Google Scholar 

  32. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27–36.

    Article  CAS  PubMed  Google Scholar 

  33. Abelo A, Andersson TB, Antonsson M, Naudot AK, Skanberg I, Weidolf L. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. Drug Metab Dispos. 2000;28(8):966–72.

    CAS  PubMed  Google Scholar 

  34. Andersson T, Hassan-Alin M, Hasselgren G, Rohss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40(7):523–37.

    Article  CAS  PubMed  Google Scholar 

  35. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129(12):1027–30.

    Article  CAS  PubMed  Google Scholar 

  36. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PloS One. 2013;8(4):e62162.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311–5.

    Article  CAS  PubMed  Google Scholar 

  38. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev. 2000;22(2):283–97.

    Article  CAS  PubMed  Google Scholar 

  39. Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of Helicobacter pylori infection. Helicobacter. 2014;19:1–5.

    Article  PubMed  Google Scholar 

  40. McJunkin B, Sissoko M, Levien J, Upchurch J, Ahmed A. Dramatic decline in prevalence of Helicobacter pylori and peptic ulcer disease in an endoscopy-referral population. Am J Med. 124(3):260–4.

  41. Segal I, Ally R, Mitchell H. Helicobacter pylori—an African perspective. QJM: Int J Med. 2001;94(10):561–5.

    Article  CAS  Google Scholar 

  42. Cave DR. How is Helicobacter pylori transmitted? Gastroenterology. 1997;113(6 Suppl):S9–14.

    Article  CAS  PubMed  Google Scholar 

  43. van Duynhoven YT, de Jonge R. Transmission of Helicobacter pylori: a role for food? Bull World Health Organ. 2001;79(5):455–60.

    PubMed  PubMed Central  Google Scholar 

  44. Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A. 2006;103(3):732–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Blaser MJ. Helicobacter pylori: microbiology of a ‘slow’ bacterial infection. Trends Microbiol. 1993;1(7):255–60.

    Article  CAS  PubMed  Google Scholar 

  46. Stingl K, Altendorf K, Bakker EP. Acid survival of Helicobacter pylori: how does urease activity trigger cytoplasmic pH homeostasis? Trends Microbiol. 2002;10(2):70–4.

    Article  CAS  PubMed  Google Scholar 

  47. Kao C-Y, Sheu B-S, Wu J-J. Helicobacter pylori infection: an overview of bacterial virulence factors and pathogenesis. Biom J. 2016;39(1):14–23.

    Google Scholar 

  48. Logan RP. Adherence of Helicobacter pylori. Aliment Pharmacol Ther. 1996;10(Suppl 1):3–15.

    Article  PubMed  Google Scholar 

  49. Bytzer P, Dahlerup JF, Eriksen JR, Jarbol DE, Rosenstock S, Wildt S. Diagnosis and treatment of Helicobacter pylori infection. Dan Med Bull. 2011;58(4):C4271.

    PubMed  Google Scholar 

  50. McColl KE, El-Omar E, Gillen D. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull. 1998;54(1):121–38.

    Article  CAS  PubMed  Google Scholar 

  51. Chen XY, Liu WZ, Shi Y, Zhang DZ, Xiao SD, Tytgat GNJ. Helicobacter pylori associated gastric diseases and lymphoid tissue hyperplasia in gastric antral mucosa. J Clin Pathol. 2002;55(2):133–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991;324(15):1043–8.

    Article  CAS  PubMed  Google Scholar 

  53. Jaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ. 1999;319(7216):1040–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Kim SS, Ruiz VE, Carroll JD, Moss SF. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Cancer Lett. 2011;305(2):228–38.

    Article  CAS  PubMed  Google Scholar 

  55. Gasbarrini A, Carloni E, Gasbarrini G, Chisholm SA. Helicobacter pylori and extragastric diseases—other Helicobacters. Helicobacter. 2004;9:57–66.

    Article  PubMed  Google Scholar 

  56. Shahabi S, Rasmi Y, Jazani NH, Hassan ZM. Protective effects of Helicobacter pylori against gastroesophageal reflux disease may be due to a neuroimmunological anti-inflammatory mechanism. Immunol Cell Biol. 2007;86(2):175–8.

    Article  PubMed  CAS  Google Scholar 

  57. Amedei A, Codolo G, Del Prete G, de Bernard M, D’Elios MM. The effect of Helicobacter pylori on asthma and allergy. J Asthma Allergy. 2010;3:139–47.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Lee JY, Kim N. Diagnosis of Helicobacter pylori by invasive test: histology. Ann Transl Med. 2015;3(1):10.

    PubMed  PubMed Central  Google Scholar 

  59. Testerman TL, Morris J. Beyond the stomach: an updated view of Helicobacter pylori pathogenesis, diagnosis, and treatment. World J Gastroenterol: WJG. 2014;20(36):12781–808.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Li C, Ha T, Ferguson DA Jr, et al. A newly developed PCR assay of H. pylori in gastric biopsy, saliva, and feces. Evidence of high prevalence of H. pylori in saliva supports oral transmission. Dig Dis Sci. 1996;41(11):2142–9.

    Article  CAS  PubMed  Google Scholar 

  61. Liu H, Rahman A, Semino-Mora C, Doi SQ, Dubois A. Specific and sensitive detection of H. pylori in biological specimens by real-time RT-PCR and in situ hybridization. PloS One. 2008;3(7):e2689.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Bassis CM, Erb-Downward JR, Dickson RP, et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. mBio. 2015;6(2):e00037.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  63. Jovel J, Patterson J, Wang W, et al. Characterization of the gut microbiome using 16S or shotgun metagenomics. Front Microbiol. 2016;7:459.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Li X-X, Wong GL-H, To K-F, et al. Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use. PLoS One. 2009;4(11):e7985.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. • Khosravi Y, Dieye Y, Poh BH, et al. Culturable bacterial microbiota of the stomach of Helicobacter pylori positive and negative gastric disease patients. Sci World J. 2014;2014:610421. This study showed the correlation between Streptococcus and peptic ulcer disease. Burkholderia pseudomallei was also isolated from the gastric samples, suggesting geographical variations in the biodiversity of gastric microbiome.

    Google Scholar 

  66. Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, Mantilla A, Torres J. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep. 2014;4:4202.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  67. Engstrand L, Lindberg M. Helicobacter pylori and the gastric microbiota. Best Pract Res Clin Gastroenterol. 2013;27(1):39–45.

    Article  CAS  PubMed  Google Scholar 

  68. Delgado S, Cabrera-Rubio R, Mira A, Suarez A, Mayo B. Microbiological survey of the human gastric ecosystem using culturing and pyrosequencing methods. Microb Ecol. 2013;65(3):763–72.

    Article  CAS  PubMed  Google Scholar 

  69. •• Rolig AS, Cech C, Ahler E, Carter JE, Ottemann KM. The degree of Helicobacter pylori-triggered inflammation is manipulated by preinfection host microbiota. Infect Immun. 2013;81(5):1382–9. The authors revealed that the clinical course and outcome of H. pylori disease are influenced by the host gastric bacterial composition. They suggested that gastric microbiome could be used as a diagnostic marker to predict the outcome of H. pylori infection.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Delgado S, Leite AM, Ruas-Madiedo P, Mayo B. Probiotic and technological properties of Lactobacillus spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis. Front Microbiol. 2014;5:766.

    PubMed  Google Scholar 

  71. Khosravi Y, Dieye Y, Loke MF, Goh KL, Vadivelu J. Streptococcus mitis induces conversion of Helicobacter pylori to coccoid cells during co-culture in vitro. PLoS One. 2014;9(11):e112214.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  72. Andersson AF, Lindberg M, Jakobsson H, Backhed F, Nyren P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One. 2008;3(7):e2836.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Brawner KM, Kumar R, Serrano CA, et al. Helicobacter pylori infection is associated with an altered gastric microbiota in children. Mucosal Immunol. 2017;

  74. Llorca L, Perez-Perez G, Urruzuno P, et al. Characterization of the gastric microbiota in a pediatric population according to Helicobacter pylori status. Pediatr Infect Dis J. 2017;36(2):173–8.

    Article  PubMed  Google Scholar 

  75. Nardone G, Compare D. The human gastric microbiota: is it time to rethink the pathogenesis of stomach diseases? United European Gastroenterol J. 2015;3(3):255–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol. 1993;88(10):1801–2.

    CAS  PubMed  Google Scholar 

  77. Stoschus B, Dominguez-Munoz JE, Kalhori N, Sauerbruch T, Malfertheiner P. Effect of omeprazole on Helicobacter pylori urease activity in vivo. Eur J Gastroenterol Hepatol. 1996;8(8):811–3.

    CAS  PubMed  Google Scholar 

  78. Vesper BJ, Jawdi A, Altman KW, Haines GK 3rd, Tao L, Radosevich JA. The effect of proton pump inhibitors on the human microbiota. Curr Drug Metab. 2009;10(1):84–9.

    Article  CAS  PubMed  Google Scholar 

  79. Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 2001;15(3):379–88.

    Article  CAS  PubMed  Google Scholar 

  80. •• Paroni Sterbini F, Palladini A, Masucci L, et al. Effects of proton pump inhibitors on the gastric mucosa-associated microbiota in dyspeptic patients. Appl Environm Microbiol. 2016;82(22):6633–44. Firmicutes , particularly the Streptococcus genus, were found in a relative abundance in patients taking PPIs. The authors suggested that it may explain the exacerbation and persistence of dyspeptic symptoms in patients on PPI therapy.

    Article  CAS  Google Scholar 

  81. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124(4):837–48.

    Article  CAS  PubMed  Google Scholar 

  82. Mandar R, Mikelsaar M. Transmission of mother’s microflora to the newborn at birth. Biol Neonate. 1996;69(1):30–5.

    Article  CAS  PubMed  Google Scholar 

  83. Neu J, Rushing J. Cesarean versus vaginal delivery: long term infant outcomes and the hygiene hypothesis. Clin Perinatol. 2011;38(2):321–31.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. O’Hara AM, Shanahan F. The gut flora as a forgotten organ. EMBO Rep. 2006;7(7):688–93.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62(1):159–76.

    Article  PubMed  Google Scholar 

  87. Canny GO, McCormick BA. Bacteria in the intestine, helpful residents or enemies from within? Infect Immun. 2008;76(8):3360–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Dukowicz AC, Lacy BE, Levine GM. Small intestinal bacterial overgrowth: a comprehensive review. Gastroenterol Hepatol. 2007;3(2):112–22.

    Google Scholar 

  89. Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J Gastroenterol. 2005;11(8):1131–40.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635–8.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Kahrstrom CT, Pariente N, Weiss U. Intestinal microbiota in health and disease. Nature. 2016;535(7610):47–7.

  92. Sekirov I, Russell SL, Antunes LCM, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859–904.

    Article  CAS  PubMed  Google Scholar 

  93. Al-Asmakh M, Hedin L. Microbiota and the control of blood-tissue barriers. Tissue Barriers. 2015;3(3):e1039691.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  94. Smith P, Willemsen D, Popkes ML, et al. Regulation of life span by the gut microbiota in the short-lived African turquoise killifish. bioRxiv. 2017;

  95. Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26 doi:10.3402/mehd.v3426.26191.

  96. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology. 2010;156(Pt 11):3205–15.

    Article  CAS  PubMed  Google Scholar 

  97. Vogtmann E, Hua X, Zeller G, et al. Colorectal cancer and the human gut microbiome: reproducibility with whole-genome shotgun sequencing. PLoS One. 2016;11(5):e0155362.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  98. De Palma G, Nadal I, Medina M, et al. Intestinal dysbiosis and reduced immunoglobulin-coated bacteria associated with coeliac disease in children. BMC Microbiol. 2010;10:63.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Tang WHW, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. J Clin Invest. 2014;124(10):4204–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Fujimura KE, Lynch SV. Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. Cell Host Microbe. 2015;17(5):592–602.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Petra AI, Panagiotidou S, Hatziagelaki E, Stewart JM, Conti P, Theoharides TC. Gut-microbiota-brain axis and effect on neuropsychiatric disorders with suspected immune dysregulation. Clin Ther. 2015;37(5):984–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Lutgendorff F, Akkermans LM, Soderholm JD. The role of microbiota and probiotics in stress-induced gastro-intestinal damage. Curr Mol Med. 2008;8(4):282–98.

    Article  CAS  PubMed  Google Scholar 

  103. Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology. 2007;132(4):1359–74.

    Article  CAS  PubMed  Google Scholar 

  104. Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci U S A. 2002;99(24):15451–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Gordon HA, Bruckner-Kardoss E. Effect of normal microbial flora on intestinal surface area. Am J Phys. 1961;201:175–8.

    CAS  Google Scholar 

  106. Wostmann B, Bruckner-Kardoss E. Development of cecal distention in germ-free baby rats. Am J Phys. 1959;197:1345–6.

    CAS  Google Scholar 

  107. Husebye E, Hellstrom PM, Midtvedt T. Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. Dig Dis Sci. 1994;39(5):946–56.

    Article  CAS  PubMed  Google Scholar 

  108. Alam M, Midtvedt T, Uribe A. Differential cell kinetics in the ileum and colon of germfree rats. Scand J Gastroenterol. 1994;29(5):445–51.

    Article  CAS  PubMed  Google Scholar 

  109. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292(5519):1115–8.

    Article  CAS  PubMed  Google Scholar 

  110. Beasley DE, Koltz AM, Lambert JE, Fierer N, Dunn RR. The evolution of stomach acidity and its relevance to the human microbiome. PLoS One. 2015;10(7):e0134116.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  111. Roggenbuck M, Baerholm Schnell I, Blom N, et al. The microbiome of new world vultures. Nat Commun. 2014;5:5498.

    Article  CAS  PubMed  Google Scholar 

  112. Lange K, Buerger M, Stallmach A, Bruns T. Effects of antibiotics on gut microbiota. Dig Dis. 2016;34(3):260–8.

    Article  PubMed  Google Scholar 

  113. Jump RLP. Clostridium difficile infection in older adults. Aging Health. 2013;9(4):403–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Russell TL, Berardi RR, Barnett JL, et al. Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women. Pharm Res. 1993;10(2):187–96.

    Article  CAS  PubMed  Google Scholar 

  115. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365(18):1693–703.

    Article  CAS  PubMed  Google Scholar 

  116. Lee C, Hong SN. Does long-term proton pump inhibitor therapy affect the health of gut microbiota? Gut Liver. 2016;10(6):865–6.

    Article  PubMed  PubMed Central  Google Scholar 

  117. Shin CM, Kim N, Kim YS, et al. Impact of long-term proton pump inhibitor therapy on gut microbiota in F344 rats: pilot study. Gut Liver. 2016;10(6):896–901.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–56. quiz 2057

    Article  PubMed  Google Scholar 

  119. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol. 2009;104(Suppl 2):S10–6.

    Article  CAS  PubMed  Google Scholar 

  120. •• Jackson MA, Goodrich JK, Maxan M-E, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749–56. It is a large study (1827 healthy twins) that showed negative correlation between PPI use and microbial diversity of the gut. Also, overrepresentation of the upper gastrointestinal tract bacteria in the lower parts of the gut was detected.

    Article  PubMed  CAS  Google Scholar 

  121. Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–5. e889

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. •• Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65(5):740–8. The findings of this European study involving both healthy subjects and patients with GI disease (1815 participants) supported the idea that PPI use is associated with the development of less healthy gut microbiome. Of note, a significant increase in pathogenic bacteria has been revealed.

    Article  CAS  PubMed  Google Scholar 

  123. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483–90.

    Article  CAS  PubMed  Google Scholar 

  124. Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol: WJG. 2015;21(22):6817–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  125. Lué A, Lanas A. Protons pump inhibitor treatment and lower gastrointestinal bleeding: balancing risks and benefits. World J Gastroenterol. 2016;22(48):10477–81.

    Article  PubMed  PubMed Central  Google Scholar 

  126. Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M. Modulation of microbiota as treatment for intestinal inflammatory disorders: an uptodate. World J Gastroenterol. 2016;22(32):7186–202.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work received grant support from the Department of Veterans Affairs RR&D Merit Review (JRP) I01 RX000194; Human Studies CORE through CURE: Digestive Diseases Research Center supported by NIH grant P30DK41301.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Joseph R. Pisegna.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Stomach and Duodenum

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Minalyan, A., Gabrielyan, L., Scott, D. et al. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. Curr Gastroenterol Rep 19, 42 (2017). https://doi.org/10.1007/s11894-017-0577-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11894-017-0577-6

Keywords

Navigation